Bechtel Y C, Lelouët H, Hrusovsky S, Brientini M P, Mantion G, Paintaud G, Miguet J P, Bechtel P R
Département de Pharmacologie Clinique, Faculté de Médecine, H pital Universitaire, Besançon, France.
Int J Clin Pharmacol Ther. 2001 Feb;39(2):53-60. doi: 10.5414/cpp39053.
To study drug metabolism in patients before and after liver transplantation using caffeine as a probe drug. Forty-five patients undergoing liver transplantation for various liver diseases and who had well documented dossiers were selected for the study. Before the liver transplantation and 1 month, 1 year, and 6 years after liver transplantation, they were given 200 mg of caffeine by the oral route in the morning after voiding their bladder. Twenty-four-hour urine samples were collected and caffeine and metabolites were determined by HPLC: 1-methylurate (1U), 1-methylxanthine (1X), 1.7-dimethylurate (17U), 1.7-dimethylxanthine (17X), 7-methylxanthine (7X), 3-methylxanthine (3X), 1.3-dimethylurate (13U), 3.7-dimethylxanthine (37X), 1.3-dimethylxanthine (13X), 1.3.7-trimethylxanthine = caffeine (137X). Indices of enzyme activities were calculated from the following urinary elimination ratios: (AFMU+1U+1X)/17U for CYP1A2, 17U/17X for CYP2A6, 1U/1X for xanthine oxidase (XO), AFMU/(AFMU+1U+1X) for N-acetyltransferase (NAT-2).
Compared with results obtained in a group of 70 healthy subjects, caffeine metabolism before liver transplantation was deeply depressed with a decreased elimination rate in the case of all metabolites and a decreased CYP1A2 activity. Caffeine metabolism began to return to the control values one month after transplantation. One year and 6 years after liver transplantation, quantitatively, the metabolism of caffeine was stable and not different from control, but with qualitative modifications. CYP1A2 activity was decreased with reduced urinary elimination rates of 1X and 17X. XO and CYP2A6 activities and 1U and 17U urinary elimination rates were increased. Immunosuppressive treatment was possibly responsible for the metabolic pathway changes. Almost the same modifications were observed in 9 patients after bone marrow transplantation who had been treated with the same immunosuppressive drugs, cyclosporine and azathioprine. During severe rejection phases in 6 of the liver transplant patients, caffeine metabolism was progressively decreased when the usual liver function tests showed moderate but uniform changes.
Despite an apparent normal drug-metabolic function, immunosuppressive treatment induces stable variations in drugmetabolic pathways after liver transplantation which can be detected from the changes in caffeine metabolism.
以咖啡因作为探针药物,研究肝移植患者肝移植前后的药物代谢情况。选取45例因各种肝脏疾病接受肝移植且病历资料完备的患者进行研究。在肝移植前以及肝移植后1个月、1年和6年,于清晨排空膀胱后口服200mg咖啡因。收集24小时尿液样本,采用高效液相色谱法测定咖啡因及其代谢产物:1-甲基尿酸(1U)、1-甲基黄嘌呤(1X)、1,7-二甲基尿酸(17U)、1,7-二甲基黄嘌呤(17X)、7-甲基黄嘌呤(7X)、3-甲基黄嘌呤(3X)、1,3-二甲基尿酸(13U)、3,7-二甲基黄嘌呤(37X)、1,3-二甲基黄嘌呤(13X)、1,3,7-三甲基黄嘌呤=咖啡因(137X)。根据以下尿液消除率计算酶活性指标:CYP1A2的(AFMU+1U+1X)/17U、CYP2A6的17U/17X、黄嘌呤氧化酶(XO)的1U/1X、N-乙酰转移酶(NAT-2)的AFMU/(AFMU+1U+1X)。
与70名健康受试者的结果相比,肝移植前咖啡因代谢显著降低,所有代谢产物的消除率均下降,CYP1A2活性降低。肝移植后1个月,咖啡因代谢开始恢复至对照值。肝移植后1年和6年,从数量上看,咖啡因代谢稳定,与对照无差异,但有质量上的改变。CYP1A2活性降低,1X和17X的尿液消除率降低。XO和CYP2A6活性以及1U和17U的尿液消除率升高。免疫抑制治疗可能是代谢途径改变的原因。9例接受相同免疫抑制药物环孢素和硫唑嘌呤治疗的骨髓移植患者也观察到了几乎相同的改变。在6例肝移植患者的严重排斥期,当常规肝功能检查显示中度但一致的变化时,咖啡因代谢逐渐降低。
尽管药物代谢功能看似正常,但免疫抑制治疗会导致肝移植后药物代谢途径发生稳定变化,这可从咖啡因代谢的变化中检测到。